Abstract:Background: Maximizing survival for patients with primary cutaneous melanomas (melanomas) depends on an early diagnosis and appropriate management. Several new drugs have been shown to improve survival in high-risk melanoma patients. Despite well-documented guidelines, many patients do not receive optimal management, particularly when considering patient age. Objective: to provide an update on melanoma management from the time of the decision to biopsy a suspicious skin lesion. Methods: We reviewed melanoma-management research published between 2018 and 2023 and identified where such findings impact and update the management of confirmed melanomas. Pubmed, Google Scholar, Ovid and Cochrane Library were used as search tools. Results: We identified 81 publications since 2017 that have changed melanoma management; 11 in 2018, 12 in 2019, 10 in 2020, 12 in 2021, 17 in 2022 and 18 in 2023. Discussion: Delayed or inaccurate diagnosis is more likely to occur when a partial shave or punch biopsy is used to obtain the histopathology. Wherever feasible, a local excision with a narrow margin should be the biopsy method of choice for a suspected melanoma. The Breslow thickness of the melanoma remains the single most important predictor of outcome, followed by patient age and then ulceration. The BAUSSS biomarker, (Breslow thickness, Age, Ulceration, Subtype, Sex and Site) provides a more accurate method of determining mortality risk than older currently employed approaches, including sentinel lymph node biopsy. Patients with metastatic melanomas and/or nodal disease should be considered for adjuvant drug therapy (ADT). Further, high-risk melanoma patients are increasingly considered for ADT, even without disease spread. Invasive melanomas less than 1 mm thick are usually managed with a radial excision margin of 10 mms of normal skin. If the thickness is 1 to 2 mm, select a radial margin of 10 to 20 mm. When the Breslow thickness is over 2 mm, a 20 mm clinical margin is usually undertaken. In situ melanomas are usually managed with a 5 to 10 mm margin or Mohs margin control surgery. Such wide excisions around a given melanoma is the only surgery that can be regarded as therapeutic and required. Patients who have had one melanoma are at increased risk of another melanoma. Ideal ongoing management includes regular lifelong skin checks. Total body photography should be considered if the patient has many naevi, especially when atypical/dysplastic naevi are identified. Targeted approaches to improve occupational or lifestyle exposure to ultraviolet light are important. Management also needs to include the consideration of vitamin D supplementary therapy.

Melanoma medicine: New drugs for melanoma and the role of the general practitioner

Metastatic melanoma – a review of current and future drugs

Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy

A Review of Current and Pipeline Drugs for Treatment of Melanoma

The treatment of advanced melanoma: Current approaches and new challenges

Advances in the discovery and development of melanoma drug therapies

Cutaneous melanoma and the immunotherapy revolution (Review)

Primary Cutaneous Melanoma—Management in 2024

Therapeutic options in cutaneous melanoma: latest developments

Melanoma genotypes and phenotypes get personal

Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy

Immunotherapy of Melanoma: a Critical Review of Current Concepts and Future Strategies

Immunotherapy of melanoma: a critical review of current concepts and future strategies.

Advances in Targeted Therapies and Combination Approaches for Melanoma: A Comprehensive Review

Interaction of Molecular Alterations with Immune Response in Melanoma

Beyond the Scalpel: Advancing Strategic Approaches and Targeted Therapies in Nonexcisable Melanomas

Anti-PD-1 and Novel Combinations in the Treatment of Melanoma—An Update

A General Approach to Patients Presenting With Locally Advanced or Distant Metastatic Disease

Melanoma Management: From Epidemiology to Treatment and Latest Advances

The safety of anti PD-1 therapeutics for the treatment of melanoma

Drug Combinations as the New Standard for Melanoma Treatment